KRRO
Korro Bio, Inc.NASDAQHealthcare$14.00+10.67%ClosedMarket Cap: $131.6M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
2.52
P/S
20.28
EV/EBITDA
-1.85
DCF Value
$-0.70
FCF Yield
-61.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
89.8%
Operating Margin
-1366.4%
Net Margin
-1834.5%
ROE
-115.9%
ROA
-103.3%
ROIC
-83.8%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $1.3M | 49.8% | $-15.9M | $-50.0M | $-5.33 | — |
| FY 2025 | $6.4M | 33.0% | $-87.3M | $-117.3M | $-12.48 | — |
| Q3 2025 | $1.1M | 100.0% | $-19.2M | $-18.1M | $-1.92 | — |
| Q2 2025 | $1.5M | 100.0% | $-27.2M | $-25.8M | $-2.74 | — |
| Q1 2025 | $2.5M | 100.0% | $-25.0M | $-23.4M | $-2.49 | — |
| Q4 2024 | $2.3M | 100.0% | $-23.0M | $-21.2M | $-2.26 | — |
| FY 2024 | $2.3M | 100.0% | $-91.9M | $-83.6M | $-9.37 | — |
| Q3 2024 | $0.00 | NaN% | $-23.3M | $-21.0M | $-2.26 | — |
| Q2 2024 | $0.00 | NaN% | $-24.1M | $-21.8M | $-2.43 | — |
| Q1 2024 | $0.00 | NaN% | $-21.5M | $-19.6M | $-2.44 | — |
| Q4 2023 | $0.00 | NaN% | $-26.9M | $-25.4M | $-4.89 | — |
| FY 2023 | $0.00 | NaN% | $-84.5M | $-81.2M | $-53.08 | — |